Varenicline and suicidal behaviour: A cohort study based on data from the General Practice Research Database

BMJ (Online)

Volumn 339, Issue 7729, 2009, Pages 1072-

  Gunnell, D ^a   Irvine, D ^b   Wise, L ^b   Davies, C ^b   Martin, R M ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; NICOTINE; VARENICLINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEPRESSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; SMOKING CESSATION; SUICIDAL BEHAVIOR; SUICIDE; TOBACCO DEPENDENCE; TREATMENT OUTCOME; UNITED KINGDOM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BENZAZEPINES; BUPROPION; COHORT STUDIES; DOPAMINE UPTAKE INHIBITORS; FAMILY PRACTICE; FEMALE; GANGLIONIC STIMULANTS; HUMANS; MALE; MIDDLE AGED; NICOTINE; QUINOXALINES; SMOKING CESSATION; SUICIDE; YOUNG ADULT;

EID: 70449392796     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.b3805     Document Type: Article

References (18)

1. Cahill K, Stead L, Lancaster T. A preliminary benefit-risk assessment of varenicline in smoking cessation. Drug Safety 2009;32:119-135
2. Hughes JR. Smoking and suicide: a brief overview. Drug and Alcohol Dependence 2008;98:169-178
3. Hays JT, Ebert JO. Varenicline for tobacco dependence. N Engl J Med 2008;359:2018-2024
4. Medicines and Healthcare products Regulatory Agency (MHRA). Varenicline: possible effects on driving; psychiatric illness. Drug Safety Update 2007;1:12.
5. Hemmingsson T, Kriebel D. Smoking at age 18-20 and suicide during 26 years of follow-up-how can the association be explained? Int J Epidemiol 2003;32:1000-1004
6. Miller M, Hemenway D, Rimm E. Cigarettes and suicide: a prospective study of 50 000 men. Am J Public Health 2000;90:768-773 (Pubitemid 30246381)
7. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 1991;302:766-768
8. Garcia Rodriguez LA, Perez-Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacology 1998;45:419-425 (Pubitemid 28227341)
9. Martinez C, Rietbrock S, Wise L, Ashby D, Chick J, Moseley J, Evans S, Gunnell D. Antidepressant treatment and the risk of fatal and non-fatal self-harm in first episode depression- a nested case-control study. BMJ 2005;330:389-393 (Pubitemid 40288823)
10. Office for National Statistics. Indices of Deprivation across the UK: Similarities and differences between the Indices of Deprivation across the UK. www.neighbourhood.statistics.gov.uk/dissemination/Info.do?page= aboutneighbourhood/indicesofdeprivation/indices-of-deprivation.htm.
11. Gunnell D, Harbord R, Singleton N, Jenkins R, Lewis G. Factors influencing the development and amelioration of suicidal thoughts in the general population. Br J Psychiatry 2004;185:385-393 (Pubitemid 39482074)
12. Lewis G, Sloggett A. Suicide, deprivation and unemployment. BMJ 1998;317:1283-1286
13. Farrell M, Howes S, Bebbington P, Brugha T, Jenkins R, Lewis G, et al. Nicotine, alcohol, and drug dependence and psychiatric comorbidity. Br J Psychiatry 2001;179:432-437
14. Boden JM, Fergusson DM, Horwood LJ. Cigarette smoking and suicidal behaviour: results from a 25-year longitudinal study. Psychol Med 2008;38:433-439 (Pubitemid 351311676)
15. Leistikow BN, Shipley MJ. Might stopping smoking reduce injury death risks? A meta-analysis of randomised controlled trials. Prev Med 1999;28:255-259
16. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, et al. Varenicline, an a4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation. JAMA 2006;296:47-55.
17. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al. Efficacy of varenicline, an a4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation. JAMA 2006;296:56-63.
18. Patterson F, Jepson C, Strasser AA, Loughead J, Perkins KA, Gur RC, et al. Varenicline improves mood and cognition during smoking abstinence. Biological Psychiatry 2009;65:144-149